Literature DB >> 11222981

Elicitation of predictable immune responses by using live bacterial vectors.

B Drabner1, C A Guzmán.   

Abstract

There is an increasing need for novel vaccines able to stimulate efficient and long-lasting responses, which have also low production costs. To confer protective immunity following vaccination, the adequate type of response should be elicited. Vaccines based on attenuated bacterial carriers have contained production and delivery costs, and are able to stimulate more potent immune responses than non-replicating formulations. The improved knowledge on carrier physiology and host response, the availability of different mutants and highly sophisticated expression tools, and the possibility of co-administering modulators enable to trigger predictable responses according to the specific needs. Recent studies support the use of attenuated bacteria not only as conventional carriers, but also as a delivery system for DNA vaccines against infectious agents and tumors. In this review we discuss the most widely used bacterial carrier systems for either antigens or nucleic acid vaccines, and the strategies which have been successfully exploited to modulate the immune responses elicited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222981     DOI: 10.1016/s1389-0344(00)00072-1

Source DB:  PubMed          Journal:  Biomol Eng        ISSN: 1389-0344


  8 in total

1.  The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice.

Authors:  Michael H Norris; Katie L Propst; Yun Kang; Steven W Dow; Herbert P Schweizer; Tung T Hoang
Journal:  Infect Immun       Date:  2011-08-01       Impact factor: 3.441

2.  Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen.

Authors:  Ayman Al-Mariri; Anne Tibor; Pascal Lestrate; Pascal Mertens; Xavier De Bolle; Jean-Jacques Letesson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

3.  A candidate triple-negative breast cancer vaccine design by targeting clinically relevant cell surface markers: an integrated immuno and bio-informatics approach.

Authors:  Shashank Kumar; Mohd Shuaib; Kumari Sunita Prajapati; Atul Kumar Singh; Princy Choudhary; Sangeeta Singh; Sanjay Gupta
Journal:  3 Biotech       Date:  2022-02-20       Impact factor: 2.406

4.  Gut adhesive Bacillus subtilis spores as a platform for mucosal delivery of antigens.

Authors:  Milene Tavares Batista; Renata D Souza; Juliano D Paccez; Wilson B Luiz; Ewerton L Ferreira; Rafael C M Cavalcante; Rita C C Ferreira; Luís C S Ferreira
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

5.  Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination.

Authors:  Fengling Luo; Yong Feng; Min Liu; Pingfei Li; Qin Pan; Victor Tunje Jeza; Bing Xia; Jianguo Wu; Xiao-Lian Zhang
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

6.  The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.

Authors:  Thomas Ebensen; Kai Schulze; Peggy Riese; Michael Morr; Carlos A Guzmán
Journal:  Clin Vaccine Immunol       Date:  2007-06-13

Review 7.  Recent advances in delivery of veterinary DNA vaccines against avian pathogens.

Authors:  Seyed Davoud Jazayeri; Chit Laa Poh
Journal:  Vet Res       Date:  2019-10-10       Impact factor: 3.683

8.  Phenotypic Characterization of a Novel Virulence-Factor Deletion Strain of Burkholderia mallei That Provides Partial Protection against Inhalational Glanders in Mice.

Authors:  Joel A Bozue; Sidhartha Chaudhury; Kei Amemiya; Jennifer Chua; Christopher K Cote; Ronald G Toothman; Jennifer L Dankmeyer; Christopher P Klimko; Catherine L Wilhelmsen; Jolynn W Raymond; Nela Zavaljevski; Jaques Reifman; Anders Wallqvist
Journal:  Front Cell Infect Microbiol       Date:  2016-02-26       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.